Healthcare
Nanosonics Limited(NNCSF)
Live Price
Offline$2.36
+0.00% today
1Y Change
+0.43%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.02B
- Revenue Growth
- +17.0%
- EPS Growth
- +62.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nanosonics Limited (NNCSF) is a Healthcare stock with a market cap of $1.02B and listed on OTC. The stock last traded around $2.36 and up 0.4% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +17.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue +17.0%, EPS +62.4%, free cash flow +74.0% with operating margin 8.9% and ROIC 7.0%. Valuation already assumes a fairly strong business story at P/E 49.7 and price/sales 4.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NNCSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.0% vs +7.6% peer median
Operating Margin
Below sector median
+8.9% vs +19.4% peer median
P/E
Above sector median
49.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 24, 2026 with an EPS surprise of -0.4% and a revenue surprise of -2.3%.
The operating story is still moving forward
Revenue is running at +17.0% and EPS at +62.4%, with operating margin around 8.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 24, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 24, 2026 | -0.4% | +0.0% | +0.0% | -4.8% |
2025 Aug 24, 2025 | +16.8% | +29.8% | +10.6% | +19.1% |
2025 Feb 19, 2025 | +46.7% | +0.0% | +13.8% | +8.4% |
Benchmark Edge
NNCSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NNCSF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NNCSF Max Drawdown
-32.30%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NNCSF and SPY.
Company Overview
Nanosonics Limited
Other OTC
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
- Leadership
- Michael C. Kavanagh
- IPO Date
- Aug 13, 2012
- Employees
- 466
- Street Address
- Building A
- Mailing
- Macquarie Park, NSW, 2113
- Region
- Macquarie Park, NSW, AU
- Reporting Currency
- USD
- Investor Line
- 61 2 8063 1600
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 49.7
- EV/EBITDA
- 29.9
- Price/Sales
- 4.9
- Price/Book
- 4.6
Growth
- Revenue
- +17.0%
- EPS
- +62.4%
- Free Cash Flow
- +74.0%
Profitability
- Gross Margin
- 77.2%
- Operating Margin
- 8.9%
- Net Margin
- 9.9%
- ROE
- 9.6%
- ROIC
- 7.0%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 6.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.